CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clorox Co (CLX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company faces significant headwinds, including declining financial performance, bearish technical indicators, and negative sentiment from analysts. While there is potential for long-term recovery, the current entry point does not present an optimal opportunity given the investor's impatience and unwillingness to wait for better conditions.
The technical indicators for CLX are bearish. The MACD histogram is negative and expanding, RSI is neutral at 30.226, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 97.763), but there is no clear upward momentum. The stock has a 60% chance to drop slightly (-0.75%) in the next week and a moderate chance of recovery (+4.87%) in the next month.
Clorox is investing in innovation and marketing to maintain market share. The company has a strong brand presence and is focusing on recovery strategies. Additionally, there is a moderate chance of a 4.87% price increase in the next month based on historical patterns.
Clorox faces significant challenges, including declining financial performance (revenue, net income, EPS, and gross margin all dropped YoY in Q2 2026). Analysts have lowered price targets and ratings due to inflationary pressures, geopolitical tensions, and competition from private labels. Technical indicators are bearish, and the stock is trading near support levels with no clear upward momentum.
In Q2 2026, Clorox's financial performance declined significantly. Revenue dropped by -0.77% YoY to $1.673 billion, net income fell by -18.65% YoY to $157 million, EPS decreased by -16.77% YoY to $1.29, and gross margin declined by -1.81% YoY to 42.86%. These metrics indicate weakening profitability and growth.
Analyst sentiment is predominantly negative. Multiple firms, including JPMorgan, Barclays, and Citi, have downgraded Clorox's price targets, citing inflationary pressures, competition from private labels, and declining category growth. The average price target is below the current price, with mixed ratings ranging from Underweight to Neutral. Analysts expect further downside risks to estimates and guidance.
